• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

间质金属蛋白酶在前列腺增生和前列腺癌患者中的表达比较研究。

Comparative study of stromal metalloproteases expression in patients with benign hyperplasia and prostate cancer.

机构信息

Servicio de Urología, Hospital de Jove, Avda. Eduardo Castro s/n, 33920, Gijón, Asturias, Spain.

出版信息

J Cancer Res Clin Oncol. 2011 Mar;137(3):551-5. doi: 10.1007/s00432-010-0906-8. Epub 2010 May 28.

DOI:10.1007/s00432-010-0906-8
PMID:20508949
Abstract

PURPOSE

The aim of the present work was to perform a comparative study of stromal cell expressions of MMPs and TIMPs between benign and malignant prostate tissues.

METHODS

An immunohistochemical study was performed using specific antibodies against metalloproteases (MMPs) -1, -2, -7, 9, 11, 13, 14 and their tissue inhibitors (TIMPs) -1, 2 and 3, on prostate specimens from 133 patients with clinical localized prostate carcinoma and from 50 patients with BPH.

RESULTS

Our results showed higher percentages of expressions of MMPs and TIMPs by fibroblasts or by mononuclear inflammatory cells (MICs) in prostate carcinomas compared to these cells in BPH. The detection of MMP-2 expression by stromal fibroblasts and/or MMP-2, 9 and TIMP-3 expression by stromal MICs was associated with a 100% of specificity for diagnoses of prostate cancer. We found that the combination of MMP-2 expression by fibroblasts and/or MMP-9 by MICs and/or TIMP-2 by MICs yielded a sensitivity of 47.4%.

CONCLUSIONS

Despite of a limited sensitivity (50%), the combination of MMP-TIMPs expression in stromal cells (MMP-2 by fibroblasts and TIMPs by MICs) in our study provided a specificity of 100% for prostate cancer diagnosis.

摘要

目的

本研究旨在比较良性和恶性前列腺组织中基质细胞金属基质蛋白酶(MMPs)和组织抑制剂(TIMPs)的表达。

方法

采用针对 MMPs-1、-2、-7、9、11、13、14 及其组织抑制剂(TIMPs)-1、2 和 3 的特异性抗体,对 133 例临床局限性前列腺癌患者和 50 例 BPH 患者的前列腺标本进行免疫组织化学研究。

结果

我们的研究结果显示,与 BPH 相比,前列腺癌中基质细胞(成纤维细胞或单核炎性细胞[MICs])中 MMPs 和 TIMPs 的表达比例更高。基质成纤维细胞表达 MMP-2 和/或基质 MICs 表达 MMP-2、9 和 TIMP-3 可特异性诊断前列腺癌(特异性 100%)。我们发现,成纤维细胞表达 MMP-2 和/或 MICs 表达 MMP-9 和/或 MICs 表达 TIMP-2 的组合敏感性为 47.4%。

结论

尽管敏感性有限(50%),但本研究中基质细胞(成纤维细胞的 MMP-2 和 MICs 的 TIMPs)中 MMP-TIMP 表达的组合对前列腺癌诊断的特异性为 100%。

相似文献

1
Comparative study of stromal metalloproteases expression in patients with benign hyperplasia and prostate cancer.间质金属蛋白酶在前列腺增生和前列腺癌患者中的表达比较研究。
J Cancer Res Clin Oncol. 2011 Mar;137(3):551-5. doi: 10.1007/s00432-010-0906-8. Epub 2010 May 28.
2
Expression of metalloproteases and their inhibitors by tumor and stromal cells in ductal carcinoma in situ of the breast and their relationship with microinvasive events.乳腺导管原位癌中肿瘤细胞和基质细胞金属蛋白酶及其抑制剂的表达及其与微浸润事件的关系。
J Cancer Res Clin Oncol. 2010 Sep;136(9):1313-21. doi: 10.1007/s00432-010-0782-2. Epub 2010 Feb 3.
3
Expression of metalloproteases and their inhibitors in different histological types of breast cancer.不同组织学类型乳腺癌中金属蛋白酶及其抑制剂的表达。
J Cancer Res Clin Oncol. 2010 Jun;136(6):811-9. doi: 10.1007/s00432-009-0721-2. Epub 2009 Nov 15.
4
Diagnostic and Prognostic Accuracy of MMPs and TIMPs in Oral Cancer Patients on Enzyme-Linked Immunosorbent Assay (ELISA) as Compared to Immunohistochemistry (IHC).与免疫组织化学(IHC)相比,酶联免疫吸附测定(ELISA)检测口腔癌患者基质金属蛋白酶(MMPs)和基质金属蛋白酶组织抑制因子(TIMPs)的诊断及预后准确性
Indian J Surg Oncol. 2025 Apr;16(2):601-610. doi: 10.1007/s13193-024-02113-7. Epub 2024 Oct 23.
5
Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix.子宫颈肿瘤进展过程中基质金属蛋白酶及其内源性抑制剂的变化。
J Cancer Res Clin Oncol. 2003 Feb;129(2):123-31. doi: 10.1007/s00432-002-0411-9. Epub 2003 Feb 19.
6
Expression of metalloproteases and their inhibitors in primary tumors and in local recurrences after mastectomy for breast cancer.乳腺癌乳房切除术后原发肿瘤和局部复发中金属蛋白酶及其抑制剂的表达。
J Cancer Res Clin Oncol. 2010 Jul;136(7):1049-58. doi: 10.1007/s00432-009-0750-x. Epub 2009 Dec 30.
7
Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival.MMP-1、MMP-9 和 TIMP-2 在前列腺癌中的表达及其对预后和生存的影响。
J Cancer Res Clin Oncol. 2013 Aug;139(8):1373-82. doi: 10.1007/s00432-013-1453-x. Epub 2013 May 25.
8
Coordinate cell-surface expression of matrix metalloproteinases and their inhibitors on cancer-associated myofibroblasts from malignant ascites in patients with gastric carcinoma.协调胃癌患者恶性腹水中癌相关肌成纤维细胞上基质金属蛋白酶及其抑制剂的细胞表面表达。
J Cancer Res Clin Oncol. 2005 Dec;131(12):809-14. doi: 10.1007/s00432-005-0030-3. Epub 2005 Nov 15.
9
Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.经尿道前列腺动脉栓塞术治疗良性前列腺增生症男性下尿路症状。
Cochrane Database Syst Rev. 2022 Mar 29;3(3):CD012867. doi: 10.1002/14651858.CD012867.pub3.
10
Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia.检测前列腺按摩样本中的端粒酶活性有助于提高前列腺癌与良性前列腺增生的鉴别能力。
J Cancer Res Clin Oncol. 2004 Apr;130(4):217-21. doi: 10.1007/s00432-003-0525-8. Epub 2004 Jan 29.

引用本文的文献

1
Evaluation of Matrix Metalloproteases by Artificial Intelligence Techniques in Negative Biopsies as New Diagnostic Strategy in Prostate Cancer.人工智能技术在阴性活检中对基质金属蛋白酶的评估作为前列腺癌的新诊断策略。
Int J Mol Sci. 2023 Apr 10;24(8):7022. doi: 10.3390/ijms24087022.
2
HLA-BAT1 alters migration, invasion and pro-inflammatory cytokines in prostate cancer.人类白细胞抗原B关联转录本1(HLA - BAT1)改变前列腺癌中的迁移、侵袭和促炎细胞因子。
Front Oncol. 2022 Nov 23;12:969396. doi: 10.3389/fonc.2022.969396. eCollection 2022.
3
The Role of the Metzincin Superfamily in Prostate Cancer Progression: A Systematic-Like Review.

本文引用的文献

1
New treatments for localized prostate cancer.局限性前列腺癌的新疗法。
Urology. 2008 Dec;72(6 Suppl):S36-43. doi: 10.1016/j.urology.2008.08.506.
2
Tumor stroma and regulation of cancer development.肿瘤基质与癌症发展的调控
Annu Rev Pathol. 2006;1:119-50. doi: 10.1146/annurev.pathol.1.110304.100224.
3
Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis.乳腺癌中的肿瘤-基质相互作用:基质在肿瘤发生中的作用。
金属蛋白酶超家族在前列腺癌进展中的作用:一项类似系统综述
Int J Mol Sci. 2021 Mar 30;22(7):3608. doi: 10.3390/ijms22073608.
4
Association between MMP-2 expression and prostate cancer: A meta-analysis.基质金属蛋白酶-2(MMP-2)表达与前列腺癌之间的关联:一项荟萃分析。
Biomed Rep. 2016 Feb;4(2):241-245. doi: 10.3892/br.2015.553. Epub 2015 Dec 8.
5
Small antibody fusion proteins with complementarity-determining regions and lidamycin for tumor targeting therapy.用于肿瘤靶向治疗的具有互补决定区和力达霉素的小分子抗体融合蛋白。
Oncol Lett. 2013 Apr;5(4):1183-1188. doi: 10.3892/ol.2013.1143. Epub 2013 Jan 18.
6
Matrix metalloproteinase 2 overexpression and prognosis in colorectal cancer: a meta-analysis.基质金属蛋白酶 2 过表达与结直肠癌预后的关系:荟萃分析。
Mol Biol Rep. 2013 Jan;40(1):617-23. doi: 10.1007/s11033-012-2100-3. Epub 2012 Nov 27.
Tumour Biol. 2005 Jul-Aug;26(4):173-85. doi: 10.1159/000086950. Epub 2005 Jul 6.
4
Molecular pathology of prostate cancer.前列腺癌的分子病理学
J Clin Pathol. 2005 Jul;58(7):673-84. doi: 10.1136/jcp.2002.003954.
5
Tissue inhibitor of metalloproteinases-1 in breast cancer.乳腺癌中的金属蛋白酶组织抑制剂-1
Endocr Relat Cancer. 2005 Jun;12(2):215-27. doi: 10.1677/erc.1.00719.
6
Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens.根治性前列腺切除标本中小体积前列腺癌(<0.5 ml)的解剖分布及病理特征
Mod Pathol. 2005 Aug;18(8):1022-6. doi: 10.1038/modpathol.3800431.
7
Tumor-stroma interactions.肿瘤-基质相互作用
Curr Opin Genet Dev. 2005 Feb;15(1):97-101. doi: 10.1016/j.gde.2004.12.003.
8
Cysteine cathepsins (proteases)--on the main stage of cancer?半胱氨酸组织蛋白酶(蛋白酶)——处于癌症的主要舞台?
Cancer Cell. 2004 May;5(5):409-10. doi: 10.1016/s1535-6108(04)00117-5.
9
Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray.使用乳腺癌组织芯片评估雌激素受体状态免疫组化测定中的实验室间差异。
Am J Clin Pathol. 2002 May;117(5):723-8. doi: 10.1309/PEF8-GL6F-YWMC-AG56.
10
New functions for the matrix metalloproteinases in cancer progression.基质金属蛋白酶在癌症进展中的新功能。
Nat Rev Cancer. 2002 Mar;2(3):161-74. doi: 10.1038/nrc745.